Nanjing Vishee Medical Technology Co., Ltd
Symbool: 688580.SS
SHH
47.44
CNYMarktprijs vandaag
25.8198
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
3.23B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Nanjing Vishee Medical Technology Co., Ltd (688580-SS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1155 | 1248.1 | 1366 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 2266.4 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0 | 47.3 | 31.9 | 36.7 | ||||||||||
balance-sheet.row.inventory | 0 | 39.9 | 34.8 | 30.4 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 12.6 | 4.3 | 1.2 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 1254.8 | 1319.2 | 1434.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 321.5 | 172.5 | 100.3 | ||||||||||
balance-sheet.row.goodwill | 0 | 69.3 | 69.3 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 120.6 | 106.5 | 18.8 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 189.9 | 175.8 | 18.8 | ||||||||||
balance-sheet.row.long-term-investments | 0 | -2244.3 | 0 | 0.8 | ||||||||||
balance-sheet.row.tax-assets | 0 | 15.1 | 7.9 | 12.7 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2269 | 8.8 | 71.9 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 551.2 | 365 | 204.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.account-payables | 0 | 18 | 19.7 | 9.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 1.2 | 1.2 | ||||||||||
balance-sheet.row.tax-payables | 0 | 19.6 | 21.1 | 29.3 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 1.8 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 133.7 | 94.8 | 1.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 27.6 | 26.4 | 1.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 1.2 | 1.8 | ||||||||||
balance-sheet.row.total-liab | 0 | 179.3 | 155.7 | 105.7 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 68.6 | 68.6 | 68.3 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 438.4 | 349.1 | 344.3 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1588.9 | 34.8 | 58.1 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -469.2 | 1076 | 1062.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 22 | 0 | 0.8 | ||||||||||
balance-sheet.row.total-debt | 0 | 0 | 1.2 | 3 | ||||||||||
balance-sheet.row.net-debt | 0 | -1155 | -1246.9 | -1363 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 93.8 | 177.5 | 143.1 | |||||||||
cash-flows.row.depreciation-and-amortization | 0 | 17.1 | 11.1 | 8.8 | |||||||||
cash-flows.row.deferred-income-tax | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.stock-based-compensation | 0 | -2.8 | 21.4 | 1.1 | |||||||||
cash-flows.row.change-in-working-capital | 0 | -8.7 | -33.5 | -19.1 | |||||||||
cash-flows.row.account-receivables | 0 | 7.3 | -13.1 | -15.9 | |||||||||
cash-flows.row.inventory | 0 | 1.8 | 6.7 | -5.6 | |||||||||
cash-flows.row.account-payables | 0 | -20.1 | -19 | 3.4 | |||||||||
cash-flows.row.other-working-capital | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.other-non-cash-items | 0 | -15.6 | -11 | -12.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.acquisitions-net | 0 | -34.2 | 0 | 11.7 | |||||||||
cash-flows.row.purchases-of-investments | 0 | -3648 | -4264 | -2102.4 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 3664 | 4284.6 | 2115.8 | |||||||||
cash-flows.row.other-investing-activites | 0 | 9 | -10 | -11.7 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -104.8 | -76.8 | 1.9 | |||||||||
cash-flows.row.debt-repayment | 0 | -2 | -1.3 | -14 | |||||||||
cash-flows.row.common-stock-issued | 0 | 16.9 | -0.3 | -18 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | -14.9 | 1.6 | 18 | |||||||||
cash-flows.row.dividends-paid | 0 | -88.9 | -71.8 | -50.3 | |||||||||
cash-flows.row.other-financing-activites | 0 | -6.1 | -9.2 | 1059.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -95 | -81 | 994.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 0 | -113.6 | -0.4 | 1117.4 | |||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1247.7 | 1361.3 | 1361.7 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1361.3 | 1361.7 | 244.4 | |||||||||
cash-flows.row.operating-cash-flow | 0 | 86.2 | 157.4 | 120.8 | |||||||||
cash-flows.row.capital-expenditure | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.free-cash-flow | 0 | -9.4 | 70 | 109.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 462.2 | 321.6 | 430 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 130.5 | 88.5 | 108.5 | ||||||||||
income-statement-row.row.gross-profit | 0 | 331.7 | 233.1 | 321.6 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 208.7 | 162.9 | 163.1 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 339.2 | 251.4 | 271.6 | ||||||||||
income-statement-row.row.interest-income | 0 | 19.3 | 19.3 | 16.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 20.1 | 19.5 | 14.9 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 148.4 | 104.5 | 194.7 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 150 | 105.8 | 197.4 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 13.8 | 12 | 19.8 | ||||||||||
income-statement-row.row.net-income | 0 | 136.3 | 93.8 | 177.8 |
Vaak gestelde vragen
Wat is Nanjing Vishee Medical Technology Co., Ltd (688580.SS) totale activa?
Nanjing Vishee Medical Technology Co., Ltd (688580.SS) totale activa is 1806024041.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.715.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.282.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.306.
Wat is Nanjing Vishee Medical Technology Co., Ltd (688580.SS) nettowinst (netto-inkomen)?
De nettowinst is 136258629.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 0.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 208672734.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.